Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of polypeptide compound in preparation of drugs for treating non-alcoholic liver disease, idiopathic pulmonary interstitial fibrosis and arteriosclerosis

A non-alcoholic technology for pulmonary interstitial fibrosis, applied in the field of biochemistry, can solve the problems of NASH and fibrosis, inflammation and cytotoxicity, etc., and achieve the effect of low toxicity, large safety window and small dosage

Pending Publication Date: 2020-04-28
SUN YAT SEN UNIV
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The second hit involves the export of reactive oxygen species (ROS), which cause systemic oxidative stress, which further leads to inflammation and cytotoxicity, ultimately leading to NASH and fibrosis
At present, there is still a lack of effective drugs for the treatment of NAFLD / NASH. Farnesoid derivative X receptor (FXR) agonists such as PPAR-γ insulin sensitizers and obeticholic acid are new drugs under research, and their long-term use is safe. Both the sex and the effectiveness of the treatment are yet to be proven (Armstrong MJ, Gaunt P, Aithal GP, et al. Lancet, 2015. doi:10.1016 / S0140-6736(15)00803-X.)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of polypeptide compound in preparation of drugs for treating non-alcoholic liver disease, idiopathic pulmonary interstitial fibrosis and arteriosclerosis
  • Application of polypeptide compound in preparation of drugs for treating non-alcoholic liver disease, idiopathic pulmonary interstitial fibrosis and arteriosclerosis
  • Application of polypeptide compound in preparation of drugs for treating non-alcoholic liver disease, idiopathic pulmonary interstitial fibrosis and arteriosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] The preparation of embodiment 1 compound 1-6:

[0068] Compounds 1-6 were synthesized from the carboxy-terminus to the amino-terminus by the Fmoc solid-phase peptide synthesis method, and the amino acid connection sequence was connected sequentially as described above. Specific steps are as follows:

[0069] ①Conditions: MBHAR (Amide-MBHA-Resin amide-protected MBHA resin) or Wang resin is used to synthesize the Fmoc protecting group by activating lipids.

[0070] ②Indene detection reagent:

[0071] Reagent 1: 20g phenol / 5ml ethanol

[0072] Reagent 2: 0.05 0.001M KCN ​​(water) / 2.5ml pyridine

[0073] Reagent 3: 0.5g ninhydrin / 10ml ethanol

[0074] The use of indene detection reagent, reagent 1: reagent 2: reagent 3 = 1: 2: 1 (drops), heated in boiling water for 3-10min.

[0075] ③Process:

[0076] A. Resin treatment: Weigh a certain amount of MBHA resin (1% degree of cross-linking, 200-400 mesh, substitution value 0.5mmol / g) in the synthesizer, add DCM and stir fo...

Embodiment 2

[0095] Example 2 Antioxidant Polypeptide 1-6 Anti-nonalcoholic Hepatitis and Liver Fibrosis Activity

[0096] 2.1 In vitro cell experiments of compounds 1-6:

[0097] By constructing two cell models (palmitic acid (PA)-induced steatosis model of human hepatoma cell (HepG2) and fibrosis model of human hepatic stellate cell (LX-2)), the active ingredients of compounds 1-6 were tested. preliminary determination.

[0098] 2.1.1 Compounds 1-6 improve PA-induced fatty degeneration of HepG2 cells:

[0099] After the HepG2 cells adhered to the wall for 24 hours, and the degree of fusion reached 70-80%, the HepG2 cells were induced with PA (final concentration of 24 hours) for 24 hours, and then 100 uM compound 1-6 was added to the experimental group, and the same dose of PBS was added to the control group. After 24 hours of action , Oil red O staining was performed to detect the effect of drugs on fatty degeneration cells. figure 1 In the middle, the red area is the oil red O stain...

Embodiment 3

[0147] Example 3 Compound 5's Therapeutic Efficacy Study on Pulmonary Fibrosis

[0148] (1) Materials and methods

[0149] animal:

[0150] 8-week-old SPF-grade female C57BL / 6 mice, 20-25g, were provided by the Guangdong Provincial Experimental Animal Center, and experiments were carried out in the SPF-grade laboratory of the Experimental Animal Center of the School of Pharmacy, Sun Yat-sen University. Adaptive feeding for 1 week. Breeding environment: a room with a temperature of 20-25°C, a humidity of 70%, and a controlled light-dark cycle of 12 hours, with free access to food and water.

[0151] Drugs and reagents:

[0152] Bleomycin (BLM, purchased from TCI); pentobarbital sodium, bleomycin hydrochloride for injection, hydroxyproline (HYP) standard (purchased from Sigma, USA).

[0153] (2) Establishment of an animal model of bleomycin-induced pulmonary fibrosis:

[0154] Twenty-four SPF female C57BL / 6 mice were randomly divided into 3 groups (n=8), 3 groups in total: ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to application of a polypeptide compound, the polypeptide compound has the characteristics of high enzymolysis stability, high biological activity, no adverse reaction and the like, and the polypeptide compound can improve and treat non-alcoholic liver diseases including fatty liver, cholestatic liver cirrhosis, inflammation, liver injury and fibrosis. And meanwhile, lung diseases accompanied by fibrosis symptoms, such as idiopathic pulmonary interstitial fibrosis, can be improved and treatment.

Description

technical field [0001] The invention belongs to the technical field of biochemistry, and in particular relates to an agonist polypeptide. The present invention also relates to the preventive and / or therapeutic use of the above-mentioned agonist polypeptide for diseases such as non-alcoholic liver disease, idiopathic pulmonary interstitial fibrosis and arteriosclerosis. Background technique [0002] Nonalcoholic fatty liver disease (NAFLD) has been recognized as the main cause of chronic liver disease worldwide. According to the latest survey results, 25% of adults worldwide will be affected by NAFLD, and among children, the prevalence of NAFLD has reached 10%. NAFLD is a series of diseases caused by abnormal liver function, including simple steatosis, non-alcoholic steatohepatitis (NASH), liver fibrosis, liver cirrhosis, and even liver cancer. [0003] Although there are still many uncertainties about the pathogenesis of NAFLD, the "two-hit hypothesis" is currently recogni...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61P9/10A61P11/00A61P1/16
CPCA61K38/168A61P9/10A61P11/00A61P1/16
Inventor 蒋先兴赵倩
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com